Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RNA-seq and integrated network analysis reveals the hub genes and key pathway of paclitaxel inhibition on Adriamycin resistant diffuse large B cell lymphoma cells

1 Mar 2022

Abstract excerpt

About 40% of patients with diffuse large B-cell lymphoma (DLBCL) develop drug resistance after first-line chemotherapy, which remains a major cause of morbidity and mortality. The emergence of DLBCL drug resistance is mainly related to Adriamycin. Our previous research shows that Paclitaxel could be a potential therapeutic drug for the treatment of Adriamycin-resistant DLBCL. Based on the results of RNA-seq and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 14-3-3 protein interactions
Share to Bioinformatics and Genomic Networks
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35263200
DOI: 10.1080/21655979.2022.2048772

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RNA-seq and integrated network analysis reveals the hub genes and key pathway of paclitaxel inhibition on Adriamycin resistant diffuse large B cell lymphoma cellsPMID 35263200Read ↗

Identification of key genes controlling docetaxel resistance in patients with breast cancerSemantic proximity Read ↗

Identification of hub genes associated with prognosis, diagnosis, immune infiltration and therapeutic drug in liver cancer by integrated analysisSemantic proximity Read ↗

Exploration of biomarkers for predicting the prognosis of patients with diffuse large B-cell lymphoma by machine-learning analysisSemantic proximity Read ↗

Identifying Hub Genes Associated with Neoadjuvant Chemotherapy Resistance in Breast Cancer and Potential Drug Repurposing for the Development of Precision MedicineSemantic proximity Read ↗

Predicted of seven hub genes of drug resistance in gliomaSemantic proximity Read ↗

Identification of the susceptibility genes for COVID-19 in lung adenocarcinoma with global data and biological computation methodsSemantic proximity Read ↗

Discovery of drug targets and therapeutic agents based on drug repositioning to treat lung adenocarcinomaSemantic proximity Read ↗

Identification of hub genes and potential molecular mechanisms related to chemotherapy sensitivity in bladder cancer: A Comprehensive AnalysisSemantic proximity Read ↗

Identification of potential drugs for diffuse large b-cell lymphoma based on bioinformatics and Connectivity Map databaseSemantic proximity Read ↗

Mechanism of action of paclitaxel for treating glioblastoma based on single-cell RNA sequencing data and network pharmacologySemantic proximity Read ↗

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia.Semantic proximity Read ↗

Hub genes in a pan-cancer co-expression network show potential for predicting drug responsesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.